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Abstract The hypothalamic satiety peptide CART (cocaine and
amphetamine regulated transcript) is expressed at high levels in
anorectic rat glucagonomas but not in hypoglycemic insulinomas.
However, a non-anorectic metastasis derived from the glucago-
noma retained high CART expression levels and produced
circulating CART levels comparable to that of the anorectic
tumors. Moreover, distinct glucagonoma lines derived by stable
HES-1 transfection of the insulinoma caused severe anorexia but
retained low circulating levels of CART comparable to that of
insulinoma bearing or control rats. Islet tumor associated
anorexia and circulating CART levels are thus not correlated,
and in line with this peripheral administration of CART (5^50
mg/kg) produced no effect on feeding behavior. In the rat two
alternatively spliced forms of CART mRNA exist and quanti-
tative PCR revealed expression of both forms in the hypo-
thalamus, in the different islet tumors, and in the islets of
Langerhans. Immunocytochemistry as well as in situ hybridiza-
tion localized CART expression to the somatostatin producing
islet D cell. A potential endocrine/paracrine role of islet CART
remains to be clarified.
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1. Introduction
Our recent work on the characterization of CART (cocaine
and amphetamine regulated transcript) as a potent anorectic
hypothalamic peptide [1,2] originated from attempts to char-
acterize the active principle in transplantable rat glucagono-
mas causing severe anorexia [3,4]. As we had derived anorectic
as well as non-anorectic glucagonomas of common origin
[5,6], such representative in vitro cultures were screened by
subtraction cloning to identify unique mRNAs associated
with the anorectic phenotype. CART was thus identi¢ed
and subsequently cloned, expressed in yeast [2] and recombi-
nant CART was shown to have powerful e¡ects on feeding
behavior when administered centrally [1]. CART was origi-
nally identi¢ed as a brain peptide with high expression in
the hypothalamus [7] but immunoreactive CART and
CART mRNA have subsequently been localized to a number
of central peripheral neurons as well as to pituitary and adre-
nal glands [8^11].
In the present study we show that islet tumor expression of
CART is not con¢ned to the anorectic phenotype and thus
possibly does not at all contribute to the observed anorexia.
Additionally, we show that CART is a product of the normal
islet of Langerhans, where the rat pre-mRNA is di¡erentially
spliced to give rise to two transcripts encoding distinct CART
polypeptides di¡ering by a 13 amino acid insert. Both mRNA
forms are expressed in a balanced ratio in islet as ¢rst dem-
onstrated in the hypothalamus [7]. We also present evidence
that mRNA and immunoreactive CART are con¢ned to the
somatostatin producing islet D cell in the rat.
2. Materials and methods
2.1. CART mRNA expression analysis by multiplex RT-PCR
RNA was prepared as previously described [12] using the RNAzol
method (Cinna Biotecx). Tissues included rat hypothalamus (n = 6),
isolated newborn rat islets (n = 5 (batches)), a panel of islet tumors
[12], and liver, kidney, heart, and white adipose tissue as negative
controls. First-strand cDNA was prepared from 1 Wg total RNA using
random primers (Gibco) as described [12]. The multiplex PCR was
run in 50 Wl volume, using 1 Wl cDNA and a standard PCR mix, with
bu¡er (1U) including MgCl2 (1.5 mM) and a dNTP mix with 40 WM
of dCTP, dGTP, dTTP, and 20 WM dATP, 2.5 units of Taq polymer-
ase (all Promega, all ¢nal concentrations) and the PCR products were
labeled by the addition of 2.5 WCi of 1000^3000 Ci/mmol [K-33P]dATP
(Amersham). 10 pmol of each oligo was used and the PCR reaction
run with the simultaneous addition of two primer sets, one speci¢c for
rat CART and the other for the internal standard G6PDH. Rat
CART oligos: 5P-oligo 5P-GGATGATGCGTCCCATG-3P, 3P-oligo
5P-GGAACCGAAGGAGGCTGTCACC-3P ; rat G6PDH oligos: 5P-
oligo 5P-GACCTGCAGAGCTCCAATCAAC-3P, 3P-oligo 5P-CAC-
GACCCTCAGTACCAAAGGG-3P. 50 Wl mineral oil was added to
each tube. PCR conditions were: denaturation at 95‡C for 1.5 min,
followed by 22 cycles of 94‡C/30 s, 55‡C/1 min, and 72‡C/1 min. The
PCR reactions were analyzed on a 6% polyacrylamide/7 M urea gel
and then exposed overnight to a Phosphor-Imager screen for quanti-
¢cation. The method and the use of MPX-PCR for the quanti¢cation
of mRNA have been thoroughly described and discussed in [12], but
in short the simultaneous use of two primer sets with the one speci¢c
for an internal standard ensures than any variation in set-up of cDNA
and PCR is re£ected also in the internal standard, so a result is always
related to the amount of standard. We furthermore limited the num-
ber of PCR cycles to ensure that we were in the linear range of
ampli¢cation for both products.
2.2. Immunocytochemistry and in situ hybridization
2.2.1. Immunocytochemistry. The CART rabbit serum 2055A was
raised against a glutathione S-transferase-CART fusion protein as
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described [1] using the full length coding region of the short transcript
CART(1^89). CART rabbit serum 2025A was raised against the 13
amino acid insert unique to the long isoform of CART (PRRQLRAP-
GAVLQ) coupled to ovalbumin as carrier. Microwave pretreated
(2U500 W for 5 min), dewaxed para⁄n sections (4 Wm) of rat pan-
creas were double stained by overnight incubations of combinations
of polyclonal rabbit anti-rat CART (2055A or 2025A) and monoclo-
nal anti-islet hormone antibodies (GLU-001 anti-glucagon, SOM-018
anti-somatostatin, or HUI 18 anti-insulin, all Novo Nordisk A/S).
CART and islet hormone immunoreactivity were visualized by incu-
bation with combinations of £uorochrome conjugated species speci¢c
secondary antibodies (FITC anti-rabbit and Texas red anti-mouse,
both from Jackson Laboratories). Single antibody staining (indirect
immunoperoxidase) was performed by using the Histo-stain kit from
Zymed Laboratories, San Francisco, CA. Speci¢city controls included
(1) antigen preabsorption (25 Wg/ml of immunizing or irrelevant anti-
gen preincubated with diluted antiserum for 1 h prior to application
on section); and (2) single (rabbit or mouse) primary antisera, devel-
oped with the mixture of £uorochrome-conjugated secondary antibod-
ies to verify the species speci¢city of the latter.
2.2.2. Combined in situ hybridization and immunocytochemistry. In
situ hybridization analysis was performed on cryostat sections of rat
pancreas [13] using antisense RNA probes against the rat CART
cDNA (bp 226^411; GenBank accession number U10071) as de-
scribed in detail [1]. Following post-hybridization washes and RNase
treatment, sections were stained using antibody to either insulin (ICN
65-1041), glucagon (DAKO A565), or somatostatin (DAKO A-0566).
Bound antibodies were detected using secondary antibodies coupled
with biotin followed by Streptavidin Texas red. Following immuno-
histochemistry sections were dehydrated in alcohol, dipped in liquid
emulsion, and exposed in the dark for 28 days. Following develop-
ment of the photographic emulsion sections were examined for coloc-
alization of emulsion grains and immuno£uorescent signal and images
collected. Combined images of light-¢eld emulsion grains and Texas
red £uorescence was prepared using Adobe Photoshop.
2.3. Animal experiments
The appetite suppression activity of CART(42^89) was evaluated
using the following method. Female NMRI mice (9 weeks old) were
fasted for 24 h after exposure to the test diet, a nutritionally complete
liquid diet (Complan). Thirty minutes before testing, a solution con-
taining CART peptide or vehicle (phosphate bu¡ered saline) was in-
jected intraperitoneally (5, 10, 20, or 50 mg/kg, i.e. 125^1250 Wg/
mouse) in a volume of 0.25 ml (e.g. 0.01 ml/g body weight), or doses
of 0.1, 0.2, 0.5, or 1 Wg were injected into the lateral cerebral ventricle
in a volume of 10 Wl. Each mouse was placed in a 15U15U15 cm test
box with a grid £oor and a glass drinking tube containing the liquid
diet. Food consumption was measured for 10 min by electronically
recording the total amount of contact with the liquid diet during the
test session. The degree of appetite suppression produced by a dose of
CART was evaluated by comparing the duration of consumption by
control mice with that of treated mice [2].
2.4. Radioimmunoassay of CART in plasma
Immunoreactive CART in plasma was measured by radioimmuno-
assay, against standards of recombinant CART(42^89) [2] using the
polyclonal 2055A CART antiserum. CART(42^89) was radioiodi-
nated by the lactoperoxidase method [14,15] and used as tracer. Assay
bu¡er was 0.05 mol/l sodium phosphate containing in addition 0.1%
human serum albumin (Behringwerke, Marburg, Germany) and 0.6
mol/l thimerosal (Sigma). 80 Wl plasma samples or standard (+80 Wl of
charcoal treated plasma) were preincubated with 100 Wl antibody sol-
ution (diluted 1000 times) in a total volume of 400 Wl. After 24 h
preincubation at 4‡C, 100 Wl of tracer (approximately 1 fmol labeled
CART) was added. After a further 24 h, free and bound peptide were
separated using plasma coated charcoal [16]. Under these conditions,
the assay had a detection limit of 5 pmol/l, 50% displacement of label
at 80 pmol/l, and an intra-assay coe⁄cient of variation of 3^7% in the
working range (5^320 pmol/l). Samples with high concentrations were
assayed after dilution with charcoal treated plasma. Recovery of
CART added to plasma deviated less than 15% from expected values,
and dilutions of samples with high concentrations paralleled the
standard curve.
CART levels were quanti¢ed in a collection of sera from NEDH
rats carrying transplantable islet tumors, previously characterized to
be associated with or without anorexia, as follows: MSL-A-M3 is a
non-anorectic metastatic variant of MSL-A, an anorectic glucagono-
ma [5]; MSL-G-AN and MSL-G2-IN are well characterized anorectic
glucagonomas and hypoglycemic insulinomas, respectively [3,4,17,18];
IN-HES control and IN-HES-AN represent insulinoma derived clones
with (AN) or without (control) expression of recombinant HES-1
(hairy-enhancer of split-1). We have shown that constitutive expres-
sion of HES-1 converts hypoglycemic insulinomas into anorectic glu-
cagonomas (J. Jensen and O.D. Madsen, unpublished data).
3. Results
3.1. CART mRNA level of expression in di¡erent rat islet
tumors does not correlate with anorexia
We previously identi¢ed CART as being selectively ex-
pressed in anorectic versus non-anorectic glucagonoma cul-
tures in vitro [2]. However, when testing corresponding in
vivo propagated tumors we found expression in both types
and therefore there was no obvious correlation with anorexia.
Thus, the non-anorectic tumor had high CART mRNA ex-
pression levels comparable to the anorectic glucagonoma
(MSL-A-M3 versus MSL-G-AN, Fig. 1) while the insulinoma
(MSL-G2-IN, Fig. 1) had low levels. CART mRNA was un-
detectable in kidney, heart, white adipose tissue, and liver
extracts (only shown for liver, Fig. 1).
3.2. Circulating level of islet tumor derived CART-like
immunoreactivity does not correlate with anorexia
Using iodinated recombinant CART as tracer a radioimmu-
noassay was established allowing determination of circulating
levels of CART-like immunoreactivity. Normal rat plasma
levels were in the range of 14^184 pM (Table 1). Plasma
from rats carrying transplantable islet glucagonomas MSL-
G-AN and MSL-A-M3 all had moderately to highly elevated
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Fig. 1. RT-PCR measurement of CART mRNA. The two CART
mRNA isoforms were quanti¢ed in total RNA extracts from vari-
ous islet derived tumors, isolated normal islets, liver, and hypothala-
mi by multiplex RT-PCR analysis (see Section 2). The primer set
used for amplifying CART detects both splice variants (33 nucleoti-
des in di¡erence) and produces the two upper bands (CART-L and
CART-S in B). G6PDH amplicon (glucose 6-phosphate dehydrogen-
ase) serves as internal control and migrates as the lower band (in
B). Quanti¢cation (% of G6PDH expression level) of the two splice
variants in each sample from B is plotted as a bar diagram in A.
Note that a similar balanced expression of the two variants are
present in hypothalamus as well as in islets and islet derived tu-
mors.
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levels of CART-like immunoreactivity. MSL-G-AN consis-
tently produces anorexia in transplanted rats while MSL-A-
M3 has little or no in£uence on food intake. Both of these
tumors with similar high CART mRNA levels also produced
the highest levels of circulating CART observed (Table 1).
The MSL-G2-IN (insulinoma) and IN-HES transplanted
rats had circulating levels of CART comparable to control
rats. IN-HES in fact represents a glucagonoma phenotype
induced by stable transfection of IN (insulinoma) in vitro
cultures with HES-1 expression vector. While the presence
of HES-1 strongly a¡ects the regulation of the islet hormone
genes and actually converts hypoglycemic insulinomas into
anorectic glucagonomas (J. Jensen and O.D. Madsen, unpub-
lished data), it apparently does not a¡ect CART gene regu-
lation.
In summary, there was no correlation between tumor in-
duced anorexia (glucagonoma associated) and circulating lev-
els of CART immunoreactivity (Table 1).
3.3. Peripheral administration of CART does not a¡ect feeding
When CART(42^89) was injected intraperitoneally in mice
at doses of 125^1250 Wg food intake was not a¡ected at any
dose (ANOVA: Ps 0.1). This is in distinct contrast to the
e¡ects of intracerebral injection of CART in the same experi-
ment, which signi¢cantly inhibited food intake (ANOVA:
P6 0.05) at doses as low as 0.2 Wg (64% inhibition,
P6 0.001). In this experiment the maximum appetite suppres-
sive e¡ect was a 76% reduction of liquid diet intake after 0.5
Wg (P6 0.01).
3.4. CART is expressed by the somatostatin producing islet
D cells
CART mRNA was clearly detectable in all RNA prepara-
tions from normal islets of Langerhans (only shown for one of
¢ve batch preparations, Fig. 1) with a relative abundance
comparable to that found in RNA extracts from six individ-
ually dissected rat hypothalami (three shown, Fig. 1). CART
mRNA is alternatively spliced in a similar balanced ratio in
rat hypothalamus as well as in islets and derived endocrine
tumors (Fig. 1). Immunocytochemistry using two di¡erent
antisera raised against recombinant CART(42^89) (Ab
2055A) and the synthetic 13 amino acid peptide (Ab 2025A)
representing the rat speci¢c alternative splice variant produced
identical staining on sections of rat pancreas (only shown for
2025A, Fig. 2). Double labeling with islet hormone antisera
showed colocalization of CART and somatostatin immunor-
eactivity (Fig. 2C^E). This D cell speci¢c staining was selec-
tively abolished by preabsorption to the immunizing antigen
but not to e.g. somatostatin (Fig. 2A,B). Finally, in situ hy-
bridization combined with immunocytochemical staining for
somatostatin con¢rmed the D cell speci¢c expression of the
CART mRNA (Fig. 2F^H).
4. Discussion
The pluripotent nature of MSL cells ^ transformed endo-
crine pancreatic cultures derived from a liver metastasis [6] of
an X-ray induced insulinoma in the rat [19] ^ has been well
documented (reviewed in [20]). We have thus established
transplantable insulinomas [17], glucagonomas [3] as well as
a somatostatin producing culture in vitro ^ all of common
origin. Of particular interest has been the feature of severe
anorexia associated only with the transplantable glucagonoma
[3,4]. Our recent identi¢cation of yet another glucagonoma
devoid of anorexia suggested that a non-proglucagon derived
peptide could be involved. Transformed islet tissue has pre-
viously been the source of identi¢cation of crucial neuropep-
tides, such as GHRH [21,22], due to apparent ectopic expres-
sion. CART was similarly identi¢ed as a potential candidate
for causing the observed glucagonoma associated anorexia
due to its selective expression in the ‘anorectic’ in vitro culture
[2].
CART proved to be a very powerful satiety peptide when
administered intracerebroventricularly [1], a function compat-
ible with its normal hypothalamic expression [7,8,23]. We
have now shown that CART is also expressed in non-anorec-
tic islet tumors and that we can ¢nd high levels of circulating
CART immunoreactivity in blood from islet tumor trans-
planted rats with normal weight gain. These data suggest
that the CART produced by the tumor does not contribute
to the observed acute onset of anorexia. This is further sup-
ported by the fact that peripherally administered CART does
not a¡ect feeding. Finally, the HES-1 induced phenotypic
conversion of insulinomas to glucagonomas is associated
with the same severe anorexia despite unchanged low circulat-
ing CART levels ^ strongly arguing that the anorectic factor is
distinct from CART. Islet tumor expression of CART is not
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Table 1
Circulating CART and anorexia
Islet tumor (phenotype) Rat
ID
CART
(pM)
Anorexia
MSL-A-M3 1 470 No
(non-anorectic glucagonoma) 2 475 No
3 405 No
MSL-G-AN 4 421 Yes
(anorectic glucagonoma) 5 460 Yes
6 292 Yes
7 503 Yes
8 138 Pre-onset
9 190 Yes
MSL-G2-IN 10 52 No
(insulinoma) 11 62 No
12 90 No
13 37 No
14 190 No
15 17 No
IN-HES control 16 13 No
(insulinoma) 17 9 No
18 31 No
19 58 No
IN-HES-AN 20 139 Yes
(anorectic glucagonoma) 21 114 Yes
22 53 Yes
23 55 Yes
Control NEDH rats 24 131 No
25 142 No
26 57 No
27 45 No
28 14 No
29 184 No
A collection of serum samples from rats transplanted with various
types of islet derived tumors with or without severe anorexia (see
Section 2) were analyzed for immunoreactive CART. Note that the
anorectic (MSL-G-AN) as well as non-anorectic (MSL-A-M3) gluca-
gonomas are associated with highly elevated CART levels compared
to controls. Interestingly, the anorectic glucagonoma (IN-HES-AN)
derived from an insulinoma (see Section 2) retains unchanged circu-
lating CART levels when compared to control and insulinoma bearing
rats.
P.B. Jensen et al./FEBS Letters 447 (1999) 139^143 141
ectopic since CART is identi¢ed as a normal islet product ^
which we ¢nd selectively colocalized with somatostatin to the
islet D cell. This highly cell speci¢c expression in the islet
contrasts with the broader expression in the di¡erent MSL
tumor phenotypes, which by other features have been shown
to re£ect the corresponding non-transformed islet phenotype
[12,18]. The function of islet CART remains unknown but
could be paracrine as it may be co-secreted with somatostatin.
CART was recently localized also to the pituitary and adrenal
glands [8] but whether these peripheral sources of CART are
also regulated by leptin as shown for hypothalamic CART [1]
is unknown.
The original molecular cloning of rat CART [7] identi¢ed a
series of potential dibasic sites for proteolytic processing. By
alternative splicing to yield small (CART-S) and large
(CART-L) isoforms of CART di¡ering by a 13 aa insert [7]
the larger isoform has yet an additional dibasic site to add to
complexity in processing. In 1981 Spiess et al. identi¢ed and
sequenced a CART fragment from ovine hypothalamic ex-
tracts [24] with an N-terminus starting at position 42 (of the
short isoform). Recombinant and bioactive CART(42^89) ap-
peared to fold into a unique structure containing three disul-
¢de bridges [2]. This secondary structure is mandatory for
biological activity measured as anorectic potential following
i.c.v. administration [1] and has moreover very recently been
veri¢ed to exist as a major extractable product (in addition to
the N-terminally truncated CART(49^89) from isolated rat
hypothalami [25]). Both of these products suppress feeding
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Fig. 2. Islet D cell expression of CART-like immunoreactivity and mRNA. Para⁄n sections of rat pancreas (A^E) were stained for CART and
islet hormones as follows. A: CART immunoperoxidase staining of a peripheral islet cell population using the peptide speci¢c 2025A antise-
rum. B: Preabsorption of antiserum 2025A with the immunizing peptide antigen completely abolishes staining. Preabsorption to synthetic soma-
tostatin had no e¡ect (not shown). C^E: Rat pancreas double stained for CART (in green, C) and somatostatin (in red, D). Double exposure
(in yellow, E) reveals complete overlap in the distribution of somatostatin and CART-like immunoreactivity. F^H: Cryostat sections of rat
pancreas double labeled for immunoreactive somatostatin (in red, F) and CART mRNA by radioactive in situ hybridization (black grains (ar-
rows), G). The overlay plot reveals complete overlap of immunoreactive somatostatin (in red, H) and CART mRNA (white grains, H) as indi-
cated by the arrows.
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when administered i.c.v. [2] ^ and curiously, a synthetic pep-
tide representing CART(42^63) was also reported to have
some activity [26] despite the fact that Cys-55 and Cys-61
normally would be engaged in disul¢de bond formation
with Cys-73 and Cys-81, respectively [2].
Interestingly, both CART-S and CART-L will contain the
bioactive C-terminal domain ^ and it is not clear why di¡er-
ential N-terminal extensions exist since both can be processed
to bioactive CART(42^89). Moreover, alternative splicing of
CART mRNA does not take place in man where only the
short peptide is found [27]. By the use of antisera raised spe-
ci¢cally against the 13 aa insert and thus speci¢c for pro-
CART-L derived peptides we have clearly demonstrated that
CART-L is translated into immunoreactive protein in the rat.
The processing of islet CART is at present unknown but
preliminary data from tumor extracts suggest an e⁄cient
processing similar to hypothalamic tissue. We thus believe
that a substantial fraction of quanti¢able CART by our
RIA is likely equivalent to CART(42^89) or CART(49^89)
^ and that these species apparently do not cross the blood-
brain barrier to any considerable extent.
In conclusion, the hypothalamic satiety peptide, CART, is
expressed in the islet of Langerhans, where it is localized by
immunocytochemistry and in situ hybridization to the soma-
tostatin producing D cell. CART is produced by a variety of
islet derived transplantable tumors but does apparently not
contribute to acute onset of anorexia caused by certain glu-
cagonoma lines. CART transcripts are di¡erentially spliced to
yield two mRNAs of 39 nucleotides in di¡erence leading to a
unique 13 amino acid insert in one isoform. Only the short
form occurs in man but we have clearly demonstrated that the
larger isoform is translated to CART-like immunoreactivity in
rat islets. The function of islet derived CART is unknown.
Elevated circulating CART may be diagnostic for neuro-en-
docrine tumors.
Acknowledgements: Erna Engholm Pedersen, Tove Funder Nielsen,
Heidi Ingeman Jensen, Helle Petersen, Lene Alb×k and Jette Man-
delbaum are thanked for skilful technical assistance. This work was in
part supported by the Danish Cancer Society and the Danish Na-
tional Research Foundation (P.B.J., O.D.M.). Work related to the
HES-1 mediated islet tumor phenotype conversion was supported
by NIH Grant DK-55284. Hagedorn Research Institute is an inde-
pendent basic research component of Novo Nordisk A/S.
References
[1] Kristensen, P., Judge, M.E., Thim, L., Ribel, U., Christjansen,
K.N., Wul¡, B.S., Clausen, J.T., Jensen, P.B., Madsen, O.D.,
Vrang, N., Larsen, P.J. and Hastrup, S. (1998) Nature 393, 72^
76.
[2] Thim, L., Nielsen, P.F., Judge, M.E., Andersen, A.S., Diers, I.,
Egel-Mitani, M. and Hastrup, S. (1998) FEBS Lett. 428, 263^
268.
[3] Madsen, O.D., Karlsen, C., Nielsen, E., Lund, K., Kofod, H.,
Welinder, B., Rehfeld, J.F., Larsson, L., Steiner, D.F., Holst, J.J.
and Michelsen, B.K. (1993) Endocrinology 133, 2022^2030.
[4] Jensen, P.B., Blume, N., Mikkelsen, J.D., Larsen, P.J., Jensen,
H.I., Holst, J.J. and Madsen, O.D. (1998) J. Clin. Invest. 101,
503^510.
[5] Madsen, O.D., Karlsen, C., Blume, N., Jensen, H.I., Larsson, L.-
I. and Holst, J.J. (1995) Scand. J. Clin. Lab. Invest. 55, (Suppl.
220) 27^36.
[6] Madsen, O.D., Larsson, L.-I., Rehfeld, J.F., Schwartz, T., Lern-
mark, Aî ., Labrecque, A. and Steiner, D.F. (1986) J. Cell Biol.
103, 2025^2034.
[7] Douglass, J., McKinzie, A.A. and Couceyro, P.R. (1995) J. Neu-
rosci. 15, 2471^2481.
[8] Koylu, E.O., Couceyro, P.R., Lambert, P.D., Ling, N.C., Des-
ouza, E.B. and Kuhar, M.J. (1997) J. Neuroendocrinol. 9, 823^
833.
[9] Couceyro, P.R., Koylu, E.O. and Kuhar, M.J. (1997) J. Chem.
Neuroanat. 12, 229^241.
[10] Couceyro, P.R., Paquet, M., Koylu, E.O., Kuhar, M.J. and
Smith, Y. (1998) Synapse 30, 1^8.
[11] Koylu, E.O., Couceyro, P.R., Lambert, P.D. and Kuhar, M.J.
(1998) J. Comp. Neurol. 391, 115^132.
[12] Jensen, J., Serup, P., Karlsen, C., Funder, T.F. and Madsen,
O.D. (1996) J. Biol. Chem. 271, 18749^18758.
[13] Kristensen, P., Eriksen, J. and DanÖ, K. (1991) J. Histochem.
Cytochem. 39, 341^349.
[14] Thorell, J.I. and Johansson, B.G. (1971) Biochim. Biophys. Acta
251, 363^369.
[15] JÖrgensen, K.H. and Larsen, U.D. (1980) Diabetologia 19, 546^
554.
[16] Holst, J.J. and Bersani, M. (1991) in: Methods in Neurosciences
(Conn, P.M., Ed.), pp. 3^22, Academic Press, New York.
[17] Madsen, O.D., Andersen, L.C., Michelsen, B., Owerbach, D.,
Larsson, L.-I., Lernmark, Aî . and Steiner, D.F. (1988) Proc.
Natl. Acad. Sci. USA 85, 6652^6656.
[18] Blume, N., Skouv, J., Larsson, L.-I., Holst, J.J. and Madsen,
O.D. (1995) J. Clin. Invest. 96, 2227^2235.
[19] Chick, W.L., Warren, S., Chute, R.N., Like, A.A., Lauris, V. and
Kitchen, K.C. (1977) Proc. Natl. Acad. Sci. USA 74, 628^632.
[20] Madsen, O.D., Jensen, J., Blume, N., Petersen, H.V., Lund, K.,
Karlsen, C., Andersen, F.G., Jensen, P.B., Larsson, L.-I. and
Serup, P. (1996) Eur. J. Biochem. 242, 435^445.
[21] Guillemin, R., Brazeau, P., Bohlen, P., Esch, F., Ling, N. and
Wehrenberg, W.B. (1982) Science 218, 585^587.
[22] Rivier, J., Spiess, J., Thorner, M. and Vale, W. (1982) Nature
300, 276^278.
[23] Gautvik, K.M., Lecea, L., Gautvik, V.T., Danielson, P.E., Tran-
que, P., Dopazo, A., Bloom, F.E. and Sutcli¡e, J.G. (1996) Proc.
Natl. Acad. Sci. USA 93, 8733^8738.
[24] Spiess, J., Villarreal, J. and Vale, W. (1981) Biochemistry 20,
1982^1988.
[25] Thim, L., Kristensen, P., Nielsen, P.F., Wul¡, B.S. and Clausen,
J.T. (1999) Proc. Natl. Acad. Sci. USA (in press).
[26] Lambert, P.D., Couceyro, P.R., McGirr, K.M., Vechia, S.E.D.,
Smith, Y. and Kuhar, M.J. (1998) Synapse 29, 293^298.
[27] Douglass, J. and Daoud, S. (1996) Gene 169, 241^245.
FEBS 21759 22-3-99 Cyaan Magenta Geel Zwart
P.B. Jensen et al./FEBS Letters 447 (1999) 139^143 143
